ConductScience.org, home

Comparison · NCT01778634-aa4ac6df

Azithromycin vs Placebo (5% Dextrose): Number of Participants With Survival And Transfer From NICU With Microbiological Eradication of Ureaplasma

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Azithromycin vs Placebo (5% Dextrose): Number of Participants With Survival And Transfer From NICU With Microbiological Eradication of Ureaplasma. Trial comparisons, record NCT01778634-aa4ac6df. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01778634-aa4ac6df

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.9170.8190.964wilson
Risk in group 20.6070.4810.719wilson
Risk difference, group 1 minus group 20.310.1610.444newcombe hybrid score
Risk ratio, group 1 over group 21.511.221.88log
Odds ratio, group 1 over group 27.142.520.4log
Number needed to treat, for one more participant with the outcome on Azithromycin than on Placebo (5% Dextrose)3.222.256.21from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1AzithromycinAzithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days~Azithromycin: Azithromycin intravenous 20 mg/kg every 24 h x 3 days5560OG001
Group 2Placebo (5% Dextrose)Placebo~Placebo: D5W 10 ml/kg every 24 h x 3 days3761OG000

Outcome

Type
PRIMARY
Title
Number of Participants With Survival And Transfer From NICU With Microbiological Eradication of Ureaplasma
Description
Bacterial clearance (eradication) will be defined as 3 negative cultures obtained 2 and 5 days post-third dose and 21 d of age. Survival is defined as survival at time of discharge or transfer from the neonatal intensive care unit (NICU).
Time frame
Participants will be followed for the duration of hospital stay, an expected average of 10 weeks
Population

Source ClinicalTrials.gov

Trial

Title
Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants
NCT number
NCT01778634
Phases
PHASE2
Conditions
Ureaplasma Infections
Interventions
Azithromycin, Placebo
Lead sponsor
University of Maryland, Baltimore
Results first posted
2018-05-17

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01778634-aa4ac6df